Delivery Order SPE2DR25D3103-SPE2DR26F0B1S
Award Date 2/3/26
Potential Completion Date 2/4/26
Potential Value $1.6K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $5,535.22 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,444.93 for REPATHA 140 mg/ml SureClick auto-injector pens on September 11, 2025, with ultimate completion by September 12, 2025. This firm fixed price, non-set-aside delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk, typically administered via pre-filled...
- The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management, and the SureClick auto-injector delivery mechanism...
- The Defense Logistics Agency awarded a $53,478.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside competitive award is being performed at the company's corporate office in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a monoclonal antibody used to treat high cholesterol in patients with cardiovascular disease, and the SureClick...
- The Defense Logistics Agency awarded a delivery order valued at $30,876.03 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick autoinjector pens on November 13, 2025, with an ultimate completion date of November 14, 2025. This competitive award utilizes firm fixed pricing and represents a single delivery transaction under a larger contract vehicle. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patients. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order valued at $3,894.64 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 4, 2025. This non-competitive delivery order was issued under a firm fixed-price contract structure and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick delivery...
- The Defense Logistics Agency awarded a delivery order valued at $14,335.60 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of January 28, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the auto-injector delivery mechanism ensures...
- The Defense Logistics Agency (DLA) awarded a $24,925.53 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed-price, competitively awarded contract was placed with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick...